應用COSMO-SAC模型預測藥物於高分子 之溶解度

以作者查詢圖書館館藏

、以作者查詢臺灣博碩士

、以作者查詢全國書目

、勘誤回報

、線上人數：38

、訪客IP：3.141.41.109

姓名

林筱慈(Xiao-Ci Lin) 查詢紙本館藏

畢業系所

化學工程與材料工程學系

論文名稱

應用COSMO-SAC模型預測藥物於高分子之溶解度
(Prediction of Drug Solubility in Polymer with COSMO-SAC model)

相關論文

★ 預測固體溶質於超臨界二氧化碳添加共溶劑系統之溶解度	★ 碳酸二乙酯與低碳醇類於常壓下之汽液相平衡
★ 探討Peng-Robinson+COSMOSAC狀態方程式中分散項與溫度之關係	★ 探討分散項之溫度函數與體積參數之修正對PR+COSMOSAC於相平衡預測之影響
★ 預測有機物與二氧化碳雙成份系統之固液氣三相平衡	★ 常壓下乙酸酯類之雙成份混合物汽液相平衡
★ 以第一原理計算鋰嵌入與擴散於具氧空缺之二氧化鈦結構	★ 探討不同量子化學方法對PR+COSMOSAC狀態方程式應用於預測純物質及混合流體相行為之影響
★ 預測固體溶質於超臨界二氧化碳中的溶解度	★ 鋯金屬有機框架材料之碳氫氣體吸附與分離預測
★ 甲基水楊酸異構物於超臨界二氧化碳中之溶解度量測	★ 原料藥與水楊酸衍生物於超臨界二氧化碳中之溶解度量測
★ 以第一原理計算探討鋰於鈮摻雜二氧化鈦之嵌入與擴散路徑	★ 探討COSMO-SAC-dsp模型中分散項和組合項之效應
★ 第一原理計算探討藍磷烯異質結構用於鋰離子電池負極材料之特性	★ 以第一原理計算探討鋰離子於鐵摻雜磷酸鋰鈷之塊材與表面附近之擴散路徑

檔案

[Endnote RIS 格式]

[Bibtex 格式]

[相關文章]

[文章引用]

[完整記錄]

[館藏目錄]

至系統瀏覽論文 (2029-6-30以後開放)

摘要(中)

由於生物製劑分類系統的第二類藥物，其低溶解度性質限制製藥發展，透過添加高分子使其改善變成無定形分散體，但分散體大多為亞穩態，可能使活性藥物傾向再結晶，產生緩慢溶解情形，為了避免再結晶或相分離，藥物/高分子相圖很重要，主要是由溶解度與玻璃轉化溫度線構成，前者可知高分子負載藥物的最大值避免發生過飽和或再結晶，後者在低於其溫度下，使分子遷移率降低，讓藥物的亞穩態無定形狀態可長時間維持穩定。然而，受到高分子的性質影響，使室溫下量測溶解度之實驗相當困難，因此透過熱力學模型估算相平衡數據，常見用於計算藥物溶解度模型為PC-SAFT以及Flory-Huggins，而玻璃轉化溫度估算可用Gordon−Taylor模型。
本研究利用量子化學計算軟體(amsterdam modeling suite, AMS)計算19種藥物與22種不同分子量與種類之高分子性質，搭配成59個固液二元相系統，使用COSMO-SAC模型探討藥物於高分子之溶解度，並比較三種COSMO-SAC模型的計算誤差值以找出最佳版本，同時與其他模型進行比較，也針對不同高分子分子量觀察溶解度之變化，此外，探討共聚物PVPVA結構排列組合差異所產生之影響，接著選擇最常使用之Gordon−Taylor模型來計算玻璃轉化溫度，最後繪製負載藥物含量與溫度關係之熱力學相圖，有益於應用藥物設計開發與優化，以及大幅降低實驗時間與成本。

摘要(英)

As a Class II drug in the Biologics Classification System, its inherently low solubility significantly hampers pharmaceutical development. These challenges can be mitigated by incorporating polymers to create amorphous dispersions. However, these solid dispersions are frequently in a thermodynamically metastable state, which can trigger the reformation of active pharmaceutical ingredients (API) crystals, resulting in a slower dissolution rate. The reliable phase diagram for the studied drug/polymer system provides essential information to prevent recrystallization or phase separation. This diagram contains the drug solubility in polymer and glass transition temperature at different amounts of a drug in a polymer. Nonetheless, conducting solubility measurements at room temperature is challenging due to the high viscosity of the polymer. Currently, commonly used models for calculating drug solubility in polymer include PC-SAFT EOS and Flory-Huggins, while the Gordon-Taylor equation is used to estimate the glass transition temperature.
In this study, the accuracy of the COSMO-SAC model in predicting drug solubility in a polymer is investigated. A total of 59 drug-polymer binary systems composed of 19 drugs and 22 polymers with varying molecular weights and types are collected from open literature. Compare the AARD calculations of the three COSMO-SAC models to identify the optimal version and contrast them with other prominent models. Additionally, observe the changes in solubility for different polymer molecular weights and explore the influence of the copolymer PVPVA on variations in structural arrangements. Subsequently, a phase diagram of a studied drug-polymer binary system is generated by the solubility predicted from COSMO-SAC and the glass transition temperature estimated from the commonly used Gordon-Taylor model. It is beneficial to apply drug design, development, and optimization as it significantly reduces the duration and costs associated with experimental procedures.

關鍵字(中)

★ COSMO-SAC
★ 藥物溶解度
★ 無定型固體分散體
★ 高分子
★ 預測

關鍵字(英)

★ COSMO-SAC
★ Drug Solubility
★ Amorphous Solid Dispersions
★ Polymer
★ Prediction

論文目次

摘要 i
Abstract ii
致謝 iv
目錄 v
圖目錄 vi
表目錄 viii
第一章、緒論 1
1-1活性藥物成分介紹 1
1-2高分子載體介紹 8
1-3藥物-高分子相行為 11
1-4回顧藥物溶於高分子之模擬方法 16
1-5回顧COSMO-SAC發展 19
1-6 COSMO-SAC模型應用藥物或高分子預測 22
1-7研究動機 23
第二章、計算原理與細節 24
2-1溶解度計算細節 24
2-2 COSMO-SAC 26
2-3 Gordon-Taylor方程式 31
第三章、結果與討論 32
3-1比較COSMO-SAC三種不同版本的預測溶解度 34
3-2比較共聚物PVPVA64結構排列差異對預測溶解度之影響 45
3-3比較其他模型預測溶解度 50
3-4高分子的分子量對預測溶解度之影響 57
3-5建構熱力學相圖 61
第四章、結論 65
參考文獻 66
附錄一、藥物物理性質 79
附錄二、藥物結構 80
附錄三、高分子物理性質 82
附錄四、預測藥物於高分子溶解度計算結果 83
附錄五、溫度與藥物重量百分比含量相圖 92

參考文獻

1.Li, C., et al., Recent progress in drug delivery. Acta Pharmaceutica Sinica B, 2019, 9, P. 1145-1162.
2.Homayun, B., X. Lin, and H.-J. Choi, Challenges and recent progress in oral drug delivery systems for biopharmaceuticals. Pharmaceutics, 2019, 11, P. 129.
3.溫裕瀚、駱俊良, 藥物傳輸系統. 科技發展, 2019, 561, P. 33-38.
4.Amidon, G.L., et al., A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research, 1995, 12, P. 413-420.
5.Khadka, P., et al., Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability. Asian Journal of Pharmaceutical Sciences, 2014, 9, P. 304-316.
6.Polli, J.E., et al., Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharmaceutical Research, 2002, 19, P. 921-925.
7.Caron, V., et al., Amorphous solid dispersions of sulfonamide/Soluplus(R) and sulfonamide/PVP prepared by ball milling. AAPS PharmSciTech, 2013, 14, P. 464-74.
8.Kawabata, Y., et al., Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. International Journal of Pharmaceutics, 2011, 420, P. 1-10.
9.Löbenberg, R. and G.L. Amidon, Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. European Journal of Pharmaceutics and Biopharmaceutics, 2000, 50, P. 3-12.
10.Kumar, S., et al., Drug carrier systems for solubility enhancement of BCS class II drugs: a critical review. Critical Reviews™ in Therapeutic Drug Carrier Systems, 2013, 30, P. 217-56.
11.Pedro, S.N., et al., The role of ionic liquids in the pharmaceutical field: An overview of relevant applications. International Journal of Molecular Sciences, 2020, 21, P. 8298.
12.Badawy, S.I.F. and M.A. Hussain, Microenvironmental pH modulation in solid dosage forms. Journal of Pharmaceutical Sciences, 2007, 96, P. 948-959.
13.Aakeröy, C.B. and D.J. Salmon, Building co-crystals with molecular sense and supramolecular sensibility. CrystEngComm, 2005, 7, P. 439-448.
14.Joshi, J.T., A review on micronization techniques. Journal of Pharmaceutical Science and Technology, 2011, 3, P. 651-81.
15.Lai, F., et al., Nanocrystals as tool to improve piroxicam dissolution rate in novel orally disintegrating tablets. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 79, P. 552-558.
16.Shakeel, F., et al., Celecoxib nanoemulsion for transdermal drug delivery: Characterization and in vitro evaluation. Journal of Dispersion Science and Technology, 2009, 30, P. 834-842.
17.Ghezzi, M., et al., Polymeric micelles in drug delivery: An insight of the techniques for their characterization and assessment in biorelevant conditions. Journal of Controlled Release, 2021, 332, P. 312-336.
18.Yang, D., et al., Effect of the melt granulation technique on the dissolution characteristics of griseofulvin. International Journal of Pharmaceutics, 2007, 329, P. 72-80.
19.Mitchell, S.A., T.D. Reynolds, and T.P. Dasbach, A compaction process to enhance dissolution of poorly water-soluble drugs using hydroxypropyl methylcellulose. International Journal of Pharmaceutics, 2003, 250, P. 3-11.
20.Salawi, A., Self-emulsifying drug delivery systems: a novel approach to deliver drugs. Drug Delivery, 2022, 29, P. 1811-1823.
21.Thakur, R. and R.B. Gupta, Formation of phenytoin nanoparticles using rapid expansion of supercritical solution with solid cosolvent (RESS-SC) process. International Journal of Pharmaceutics, 2006, 308, P. 190-199.
22.Jagdale, S.C., et al., Solubility enhancement, physicochemical characterization and formulation of fast-dissolving tablet of nifedipine-betacyclodextrin complexes. Brazilian Journal of Pharmaceutical Sciences, 2012, 48, P. 131-145.
23.Shulman, M., et al., Enhancement of naringenin bioavailability by complexation with hydroxypropoyl-β-cyclodextrin. PLoS one, 2011, 6, P. e18033.
24.Ajay, S., et al., Solubility and dissolution rate enhancement of curcumin using kollidon VA64 by solid dispersion technique. International Journal of PharmTech Research, 2012, 4, P. 1055-1064.
25.Mishra, V., et al., Niosomes: Potential nanocarriers for drug delivery. Journal of Pharmacy and Clinical Research, 2020, 11, P. 389-94.
26.Zhang, J., et al., Analysis of the literature and patents on solid dispersions from 1980 to 2015. Molecules, 2018, 23, P. 1697.
27.Knopp, M.M., et al., Effect of amorphous phase separation and crystallization on the in vitro and in vivo performance of an amorphous solid dispersion. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 130, P. 290-295.
28.Kyeremateng, S.O., M. Pudlas, and G.H. Woehrle, A fast and reliable empirical approach for estimating solubility of crystalline drugs in polymers for hot melt extrusion formulations. Journal of Pharmaceutical Sciences, 2014, 103, P. 2847-2858.
29.Fischlschweiger, M. and S. Enders, Thermodynamic principles for the design of polymers for drug formulations. Annual Review of Chemical and Biomolecular Engineering, 2019, 10, P. 311-335.
30.Prudic, A., et al., Influence of copolymer composition on the phase behavior of solid dispersions. Molecular Pharmaceutics, 2014, 11, P. 4189-98.
31.Mayersohn, M. and M. Gibaldi, New method of solid-state dispersion for increasing dissolution rates. Journal of pharmaceutical sciences, 1966, 55, P. 1323-1324.
32.Van Duong, T. and G. Van den Mooter, The role of the carrier in the formulation of pharmaceutical solid dispersions. Part II: amorphous carriers. Expert Opinion on Drug Delivery, 2016, 13, P. 1681-1694.
33.Paradkar, A., et al., Characterization of curcumin–PVP solid dispersion obtained by spray drying. International Journal of Pharmaceutics, 2004, 271, P. 281-286.
34.Chauhan, N.P.S., et al., Pharmaceutical polymers. Encyclopedia of Biomedical Polymers and Polymeric Biomaterials, 2014, P. 5929-5942.
35.Thakral, S., N.K. Thakral, and D.K. Majumdar, Eudragit®: a technology evaluation. Expert Opinion on Drug Delivery, 2013, 10, P. 131-149.
36.D’souza, A.A. and R. Shegokar, Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications. Expert Opinion on Drug Delivery, 2016, 13, P. 1257-1275.
37.Zhang, J., et al., Advances in the development of amorphous solid dispersions: The role of polymeric carriers. Asian Journal of Pharmaceutical Sciences, 2023, P. 100834.
38.He, Y. and C. Ho, Amorphous solid dispersions: utilization and challenges in drug discovery and development. Journal of Pharmaceutical Sciences, 2015, 104, P. 3237-3258.
39.Sihorkar, V. and T. Dürig, The role of polymers and excipients in developing amorphous solid dispersions: an industrial perspective. Drug Delivery Aspects. 2020, P. 79-113.
40.Qian, F., J. Huang, and M.A. Hussain, Drug–polymer solubility and miscibility: stability consideration and practical challenges in amorphous solid dispersion development. Journal of Pharmaceutical Sciences, 2010, 99, P. 2941-2947.
41.Hancock, B.C., S.L. Shamblin, and G. Zografi, Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharmaceutical Research, 1995, 12, P. 799-806.
42.Luebbert, C., F. Huxoll, and G. Sadowski, Amorphous-amorphous phase separation in API/polymer formulations. Molecules, 2017, 22, P. 296.
43.Knopp, M.M., et al., Comparative study of different methods for the prediction of drug–polymer solubility. Molecular Pharmaceutics, 2015, 12, P. 3408-3419.
44.Tian, Y., et al., Using Flory–Huggins phase diagrams as a pre-formulation tool for the production of amorphous solid dispersions: a comparison between hot-melt extrusion and spray drying. Journal of Pharmacy and Pharmacology, 2014, 66, P. 256-274.
45.Prudic, A., Y. Ji, and G. Sadowski, Thermodynamic phase behavior of API/polymer solid dispersions. Molecular Pharmaceutics, 2014, 11, P. 2294-304.
46.Richardson, M.-J. and N. Savill, Derivation of accurate glass transition temperatures by differential scanning calorimetry. Polymer, 1975, 16, P. 753-757.
47.Rumondor, A.C., L.A. Stanford, and L.S. Taylor, Effects of polymer type and storage relative humidity on the kinetics of felodipine crystallization from amorphous solid dispersions. Pharmaceutical Research, 2009, 26, P. 2599-2606.
48.Telang, C., S. Mujumdar, and M. Mathew, Improved physical stability of amorphous state through acid base interactions. Journal of Pharmaceutical Sciences, 2009, 98, P. 2149-2159.
49.Bohr, A., et al., Particle formation and characteristics of Celecoxib-loaded poly (lactic-co-glycolic acid) microparticles prepared in different solvents using electrospraying. Polymer, 2012, 53, P. 3220-3229.
50.Tobyn, M., et al., Amorphous drug-PVP dispersions: application of theoretical, thermal and spectroscopic analytical techniques to the study of a molecule with intermolecular bonds in both the crystalline and pure amorphous state. Journal of Pharmaceutical Sciences, 2009, 98, P. 3456-3468.
51.Rumondor, A.C. and L.S. Taylor, Effect of polymer hygroscopicity on the phase behavior of amorphous solid dispersions in the presence of moisture. Molecular Pharmaceutics, 2010, 7, P. 477-490.
52.Tombari, E., et al., Calorimetric relaxation in pharmaceutical molecular glasses and its utility in understanding their stability against crystallization. The Journal of Physical Chemistry B, 2008, 112, P. 10806-10814.
53.Dedroog, S., et al., Solid-state analysis of amorphous solid dispersions: Why DSC and XRPD may not be regarded as stand-alone techniques. Journal of Pharmaceutical and Biomedical Analysis, 2020, 178, P. 112937.
54.Ma, X. and R.O. Williams III, Characterization of amorphous solid dispersions: An update. Journal of Drug Delivery Science and Technology, 2019, 50, P. 113-124.
55.Flory, P.J., Thermodynamics of high polymer solutions. The Journal of Chemical Physics, 1942, 10, P. 51-61.
56.Potter, C.B., et al., Investigation of the Dependence of the Flory–Huggins Interaction Parameter on Temperature and Composition in a Drug–Polymer System. Molecular Pharmaceutics, 2018, 15, P. 5327-5335.
57.Hansen, C.M., The universality of the solubility parameter. Industrial & Engineering Chemistry Research, 1969, 8, P. 2-11.
58.Forster, A., et al., Selection of excipients for melt extrusion with two poorly water-soluble drugs by solubility parameter calculation and thermal analysis. International Journal of Pharmaceutics, 2001, 226, P. 147-161.
59.Van Krevelen, D., Properties of Polymers, 3rd completely revised ed. 1990.
60.Tian, Y., et al., Construction of drug–polymer thermodynamic phase diagrams using Flory–Huggins interaction theory: identifying the relevance of temperature and drug weight fraction to phase separation within solid dispersions. Molecular Pharmaceutics, 2013, 10, P. 236-248.
61.Gross, J. and G. Sadowski, Perturbed-chain SAFT: An equation of state based on a perturbation theory for chain molecules. Industrial & Engineering Chemistry Research, 2001, 40, P. 1244-1260.
62.Klamt, A. and G. Schüürmann, COSMO: a new approach to dielectric screening in solvents with explicit expressions for the screening energy and its gradient. Journal of the Chemical Society, 1993, P. 799-805.
63.Klamt, A., et al., Refinement and parametrization of COSMO-RS. The Journal of Physical Chemistry A, 1998, 102, P. 5074-5085.
64.Klamt, A., COSMO-RS: from quantum chemistry to fluid phase thermodynamics and drug design. 2005.
65.Lin, S.-T. and S.I. Sandler, A priori phase equilibrium prediction from a segment contribution solvation model. Industrial & Engineering Chemistry Research, 2002, 41, P. 899-913.
66.Lin, S.-T., et al., Prediction of vapor pressures and enthalpies of vaporization using a COSMO solvation model. The Journal of Physical Chemistry A, 2004, 108, P. 7429-7439.
67.Wang, S., S.I. Sandler, and C.-C. Chen, Refinement of COSMO− SAC and the Applications. Industrial & Engineering Chemistry Research, 2007, 46, P. 7275-7288.
68.Hsieh, C.-M., S.I. Sandler, and S.-T. Lin, Improvements of COSMO-SAC for vapor–liquid and liquid–liquid equilibrium predictions. Fluid Phase Equilibria, 2010, 297, P. 90-97.
69.Chen, W.-L., et al., A critical evaluation on the performance of COSMO-SAC models for vapor–liquid and liquid–liquid equilibrium predictions based on different quantum chemical calculations. Industrial & Engineering Chemistry Research, 2016, 55, P. 9312-9322.
70.Chen, W.-L. and S.-T. Lin, Explicit consideration of spatial hydrogen bonding direction for activity coefficient prediction based on implicit solvation calculations. Physical Chemistry Chemical Physics, 2017, 19, P. 20367-20376.
71.Yang, L., et al., Prediction of vapor–liquid equilibrium for polymer solutions based on the COSMO‐SAC model. AIChE Journal, 2010, 56, P. 2687-2698.
72.Kuo, Y.-C., C.-C. Hsu, and S.-T. Lin, Prediction of phase behaviors of polymer–solvent mixtures from the COSMO-SAC activity coefficient model. Industrial & Engineering Chemistry Research, 2013, 52, P. 13505-13515.
73.Elbro, H., A. Fredenslund, and P. Rasmussen, A new simple equation for the prediction of solvent activities in polymer solutions. Macromolecules, 1990, 23, P. 4707-4714.
74.Zhu, R. and Z. Lei, COSMO-based models for predicting the gas solubility in polymers. Green Energy and Environment, 2021, 6, P. 311-313.
75.Shu, C.-C. and S.-T. Lin, Prediction of drug solubility in mixed solvent systems using the COSMO-SAC activity coefficient model. Industrial & Engineering Chemistry Research, 2011, 50, P. 142-147.
76.Mahmoudabadi, S.Z. and G. Pazuki, Investigation of COSMO-SAC model for solubility and cocrystal formation of pharmaceutical compounds. Scientific Reports, 2020, 10, P. 19879.
77.Prausnitz, J.M., R.N. Lichtenthaler, and E. Gomes de Azevedo, Molecular thermodynamics of fluid-phase equlibria. 1999.
78.Ben-Naim, A.Y., Solvation thermodynamics. 1 ed. 1987: Springer Science & Business Media. XIII, 246.
79.Lin, S.-T., et al., Towards the development of theoretically correct liquid activity coefficient models. The Journal of Chemical Thermodynamics, 2009, 41, P. 1145-1153.
80.Gordon, M. and J.S. Taylor, Ideal copolymers and the second‐order transitions of synthetic rubbers. I. Non‐crystalline copolymers. Journal of Applied Chemistry, 1952, 2, P. 493-500.
81.Simha, R. and R. Boyer, On a general relation involving the glass temperature and coefficients of expansion of polymers. The Journal of Chemical Physics, 1962, 37, P. 1003-1007.
82.Kwei, T., The effect of hydrogen bonding on the glass transition temperatures of polymer mixtures. Journal of Polymer Science, 1984, 22, P. 307-313.
83.Schneider, C.A., W.S. Rasband, and K.W. Eliceiri, NIH Image to ImageJ: 25 years of image analysis. Nature Methods, 2012, 9, P. 671-675.
84.Makadia, H.K. and S.J. Siegel, Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymer, 2011, 3, P. 1377-1397.
85.Iemtsev, A., et al., Effect of Copolymer Properties on the Phase Behavior of Ibuprofen–PLA/PLGA Mixtures. Pharmaceutics, 2023, 15, P. 645.
86.Iemtsev, A., et al., Compatibility of selected active pharmaceutical ingredients with poly (D, L-lactide-co-glycolide): Computational and experimental study. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 179, P. 232-245.
87.Marsac, P.J., S.L. Shamblin, and L.S. Taylor, Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. Pharmaceutical Research, 2006, 23, P. 2417-26.
88.Sun, Y., et al., Solubilities of Crystalline Drugs in Polymers: An Improved Analytical Method and Comparison of Solubilities of Indomethacin and Nifedipine in PVP, PVP/VA, and PVAc. Journal of Pharmaceutical Sciences, 2010, 99, P. 4023-4031.
89.Marsac, P.J., T. Li, and L.S. Taylor, Estimation of drug–polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters. Pharmaceutical Research, 2009, 26, P. 139-151.
90.Mathers, A., et al., The step-wise dissolution method: An efficient DSC-based protocol for verification of predicted API–polymer compatibility. International Journal of Pharmaceutics, 2023, 648, P. 123604.
91.Rask, M.B., et al., Influence of PVP/VA copolymer composition on drug–polymer solubility. European Journal of Pharmaceutical Sciences, 2016, 85, P. 10-17.
92.Rask, M.B., et al., Comparison of two DSC-based methods to predict drug-polymer solubility. International Journal of Pharmaceutics, 2018, 540, P. 98-105.
93.Lehmkemper, K., et al., Long-term physical stability of PVP-and PVPVA-amorphous solid dispersions. Molecular Pharmaceutics, 2017, 14, P. 157-171.
94.Chen, Q., Y. Ji, and K. Ge, Influence of excipients on thermodynamic phase behavior of pharmaceutical/solvent systems: Molecular thermodynamic model prediction. Chemical Engineering Science, 2021, 244.
95.Lin, D. and Y. Huang, A thermal analysis method to predict the complete phase diagram of drug-polymer solid dispersions. International Journal of Pharmaceutics, 2010, 399, P. 109-15.
96.Tao, J., et al., Solubility of small-molecule crystals in polymers: D-mannitol in PVP, indomethacin in PVP/VA, and nifedipine in PVP/VA. Pharmaceutical Research, 2009, 26, P. 855-64.
97.Prudic, A., et al., Thermodynamic phase behaviour of indomethacin/PLGA formulations. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 93, P. 88-94.
98.Mahieu, A.l., et al., A new protocol to determine the solubility of drugs into polymer matrixes. Molecular Pharmaceutics, 2013. 10, P. 560-566.
99.Amharar, Y., et al., Solubility of crystalline organic compounds in high and low molecular weight amorphous matrices above and below the glass transition by zero enthalpy extrapolation. International Journal of Pharmaceutics, 2014. 472, P. 241-247.
100.Gosh, R., S. Tanaka, and A. Toda, Application of a deconvolution method to construct aqueous phase diagram. Thermochimica Acta, 2010, 500, P. 100-105.
101.Pavliš, J.c., et al., Can Pure Predictions of Activity Coefficients from PC-SAFT Assist Drug–Polymer Compatibility Screening? Molecular Pharmaceutics, 2023, 20, P. 3960-3974.
102.Gross, J. and G. Sadowski, Application of the perturbed-chain SAFT equation of state to associating systems. Industrial & Engineering Chemistry Research, 2002, 41, P. 5510-5515.
103.Lee, J., et al., Thermodynamics and phase behavior of block copolymer/homopolymer blends with attractive and repulsive interactions. Macromolecules, 2002. 35, P. 7748-7757.
104.Knopp, M.M., et al., Influence of polymer molecular weight on drug–polymer solubility: a comparison between experimentally determined solubility in PVP and prediction derived from solubility in monomer. Journal of Pharmaceutical Sciences, 2015, 104, P. 2905-2912.
105.Lehmkemper, K., et al., Physical stability of API/polymer-blend amorphous solid dispersions. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 124, P. 147-157.
106.Caron, V., et al., A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone. Molecular Pharmaceutics, 2011, 8, P. 532-542.
107.Paus, R., et al., Dissolution of Crystalline Pharmaceuticals: Experimental Investigation and Thermodynamic Modeling. Industrial & Engineering Chemistry Research, 2015, 54, P. 731-742.
108.Paudel, A., J. Van Humbeeck, and G. Van den Mooter, Theoretical and experimental investigation on the solid solubility and miscibility of naproxen in poly (vinylpyrrolidone). Molecular Pharmaceutics, 2010, 7, P. 1133-1148.
109.Nair, R., et al., Influence of various drugs on the glass transition temperature of poly (vinylpyrrolidone): a thermodynamic and spectroscopic investigation. International Journal of Pharmaceutics, 2001, 225, P. 83-96.
110.Granberg, R.A. and Å.C. Rasmuson, Solubility of paracetamol in pure solvents. Journal of Chemical & Engineering Data, 1999. 44, P. 1391-1395.
111.Nti-Gyabaah, J., K. Gbewonyo, and Y.C. Chiew, Solubility of artemisinin in different single and binary solvent mixtures between (284.15 and 323.15) K and NRTL interaction parameters. Journal of Chemical & Engineering Data, 2010, 55, P. 3356-3363.
112.Barone, G., et al., Enthalpies and entropies of sublimation, vaporization and fusion of nine polyhydric alcohols. Journal of the Chemical Society, 1990, 86, P. 75-79.
113.Six, K., et al., Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion, part II. Pharmaceutical Research, 2003, 20, P. 1047-1054.
114.Van den Mooter, G., et al., Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. European Journal of Pharmaceutical Sciences, 2001, 12, P. 261-269.
115.Ou, X., et al., Polymorphism in griseofulvin: new story between an old drug and polyethylene glycol. Crystal Growth & Design, 2022, 22, P. 3778-3785.
116.Marciniec, B., et al., The effect of ionizing radiation on chloramphenicol. Journal of Thermal Analysis and Calorimetry, 2006, 84, P. 741-746.
117.Six, K., et al., Increased physical stability and improved dissolution properties of itraconazole, a class II drug, by solid dispersions that combine fast‐and slow‐dissolving polymers. Journal of Pharmaceutical Sciences, 2004. 93, P. 124-131.
118.Iemtsev, A., et al., Ball milling and hot-melt extrusion of indomethacin–l-arginine–vinylpyrrolidone-vinyl acetate copolymer: Solid-state properties and dissolution performance. International Journal of Pharmaceutics, 2022, 613, P. 121424.
119.Jelinska, N., et al., Poly (vinyl alcohol)/poly (vinyl acetate) blend films. Scientific Journal of Riga Technical University, 2010, 21.
120.Yu, H., A. Huang, and C. Xiao, Characteristics of konjac glucomannan and poly (acrylic acid) blend films for controlled drug release. Journal of Applied Polymer Science, 2006, 100, P. 1561-1570.

指導教授

謝介銘(Chieh-Ming Hsieh)

審核日期

2024-7-25

推文